Once melanomas are established, however, this lineage dependency on SOX10 may decrease because the loss of Sox10 activity is associated with drug resistance (Shaffer et al., 2017; Sun et al., 2014) and a cross-resistance mechanism for both targeted- and immune-based therapies (Purwin et al., 2023; Rosenbaum et al., 2023, 2021). This evidence concerns the gene SOX10 and melanoma.